NO319724B1 - Fremgangsmate for fremstilling av paroksetin - Google Patents

Fremgangsmate for fremstilling av paroksetin Download PDF

Info

Publication number: NO319724B1
Authority: NO; Norway
Prior art keywords: compound; binap; group; formula; hydrogenation
Prior art date: 1999-02-23

Application number

NO20014078A

Other languages

English (en)

Norwegian (no)

Other versions

NO20014078D0 (no

NO20014078L (no

Inventor

Renzo Rossi

Stefano Turchetta

Maria Donnarumma

Original Assignee

Recordati Chem Pharm

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-23

Filing date

2001-08-22

Publication date

2005-09-05

2001-08-22 Application filed by Recordati Chem Pharm filed Critical Recordati Chem Pharm

2001-08-22 Publication of NO20014078D0 publication Critical patent/NO20014078D0/no

2001-10-18 Publication of NO20014078L publication Critical patent/NO20014078L/no

2005-09-05 Publication of NO319724B1 publication Critical patent/NO319724B1/no

Links

238000000034 method Methods 0.000 title claims abstract description 41
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 title claims abstract description 26
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 title claims abstract description 21
230000008569 process Effects 0.000 title claims abstract description 21
229960002296 paroxetine Drugs 0.000 title claims abstract description 20
238000006243 chemical reaction Methods 0.000 claims abstract description 25
230000015572 biosynthetic process Effects 0.000 claims abstract description 24
LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 claims abstract description 18
239000003446 ligand Substances 0.000 claims abstract description 17
238000005984 hydrogenation reaction Methods 0.000 claims abstract description 16
229910052723 transition metal Inorganic materials 0.000 claims abstract description 13
150000003624 transition metals Chemical class 0.000 claims abstract description 13
UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims abstract description 10
238000006900 dealkylation reaction Methods 0.000 claims abstract description 5
238000010534 nucleophilic substitution reaction Methods 0.000 claims abstract description 3
150000001875 compounds Chemical class 0.000 claims description 40
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 35
MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 claims description 29
239000000203 mixture Substances 0.000 claims description 28
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 27
VURFVHCLMJOLKN-UHFFFAOYSA-N diphosphane Chemical compound PP VURFVHCLMJOLKN-UHFFFAOYSA-N 0.000 claims description 24
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 22
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 19
238000003786 synthesis reaction Methods 0.000 claims description 19
HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 claims description 13
239000002904 solvent Substances 0.000 claims description 12
239000003153 chemical reaction reagent Substances 0.000 claims description 8
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 claims description 6
ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 6
238000011282 treatment Methods 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 5
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 5
239000012359 Methanesulfonyl chloride Substances 0.000 claims description 4
230000001476 alcoholic effect Effects 0.000 claims description 4
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 4
150000007514 bases Chemical class 0.000 claims description 3
CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 claims description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 claims description 3
239000012442 inert solvent Substances 0.000 claims description 3
AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 claims description 3
KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims description 2
229910052741 iridium Inorganic materials 0.000 claims description 2
GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 claims description 2
229910052703 rhodium Inorganic materials 0.000 claims description 2
239000010948 rhodium Substances 0.000 claims description 2
MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims description 2
229910052707 ruthenium Inorganic materials 0.000 claims description 2
239000012327 Ruthenium complex Substances 0.000 claims 2
-1 amino, acetylamino Chemical group 0.000 claims 1
238000011065 in-situ storage Methods 0.000 claims 1
125000003944 tolyl group Chemical group 0.000 claims 1
230000000707 stereoselective effect Effects 0.000 abstract description 4
238000004519 manufacturing process Methods 0.000 abstract description 2
ZSYVGBLSRONTAI-UHFFFAOYSA-N [4-(4-fluorophenyl)-1,2,3,6-tetrahydropyridin-3-yl]methanol Chemical class OCC1CNCC=C1C1=CC=C(F)C=C1 ZSYVGBLSRONTAI-UHFFFAOYSA-N 0.000 abstract 1
238000001212 derivatisation Methods 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
239000000047 product Substances 0.000 description 25
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
239000000243 solution Substances 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
238000004128 high performance liquid chromatography Methods 0.000 description 10
NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
239000003480 eluent Substances 0.000 description 9
239000012074 organic phase Substances 0.000 description 9
125000003386 piperidinyl group Chemical group 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
125000003118 aryl group Chemical group 0.000 description 8
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
238000005481 NMR spectroscopy Methods 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
230000008901 benefit Effects 0.000 description 6
238000010992 reflux Methods 0.000 description 6
VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 5
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
238000002425 crystallisation Methods 0.000 description 5
230000008025 crystallization Effects 0.000 description 5
229910000397 disodium phosphate Inorganic materials 0.000 description 5
238000001704 evaporation Methods 0.000 description 5
238000001914 filtration Methods 0.000 description 5
235000019799 monosodium phosphate Nutrition 0.000 description 5
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 5
229910000162 sodium phosphate Inorganic materials 0.000 description 5
229920000858 Cyclodextrin Polymers 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
239000008346 aqueous phase Substances 0.000 description 4
239000003054 catalyst Substances 0.000 description 4
230000008020 evaporation Effects 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
239000012043 crude product Substances 0.000 description 3
DHCWLIOIJZJFJE-UHFFFAOYSA-L dichlororuthenium Chemical compound Cl[Ru]Cl DHCWLIOIJZJFJE-UHFFFAOYSA-L 0.000 description 3
239000012458 free base Substances 0.000 description 3
238000011835 investigation Methods 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
229960005183 paroxetine hydrochloride Drugs 0.000 description 3
AITNMTXHTIIIBB-UHFFFAOYSA-N 1-bromo-4-fluorobenzene Chemical compound FC1=CC=C(Br)C=C1 AITNMTXHTIIIBB-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
239000007836 KH2PO4 Substances 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
WNHLGYRPKARUHY-UHFFFAOYSA-L [1-(2-diphenylphosphanylnaphthalen-1-yl)naphthalen-2-yl]-diphenylphosphane;1-methyl-4-propan-2-ylbenzene;ruthenium(2+);dichloride Chemical group [Cl-].[Ru+]Cl.CC(C)C1=CC=C(C)C=C1.C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 WNHLGYRPKARUHY-UHFFFAOYSA-L 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
125000001207 fluorophenyl group Chemical group 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
BRKADVNLTRCLOW-UHFFFAOYSA-M magnesium;fluorobenzene;bromide Chemical compound [Mg+2].[Br-].FC1=CC=[C-]C=C1 BRKADVNLTRCLOW-UHFFFAOYSA-M 0.000 description 2
229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
235000019796 monopotassium phosphate Nutrition 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
235000011007 phosphoric acid Nutrition 0.000 description 2
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
LAXRNWSASWOFOT-UHFFFAOYSA-J (cymene)ruthenium dichloride dimer Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Ru+2].[Ru+2].CC(C)C1=CC=C(C)C=C1.CC(C)C1=CC=C(C)C=C1 LAXRNWSASWOFOT-UHFFFAOYSA-J 0.000 description 1
UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
BDVKAMAALQXGLM-UHFFFAOYSA-N 1-ethylpiperidin-4-one Chemical compound CCN1CCC(=O)CC1 BDVKAMAALQXGLM-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
238000001026 1H--1H correlation spectroscopy Methods 0.000 description 1
WVYWICLMDOOCFB-UHFFFAOYSA-N 4-methyl-2-pentanol Chemical compound CC(C)CC(C)O WVYWICLMDOOCFB-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
235000011002 L(+)-tartaric acid Nutrition 0.000 description 1
239000001358 L(+)-tartaric acid Substances 0.000 description 1
FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
208000002991 Ring chromosome 4 syndrome Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
239000002585 base Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000008098 formaldehyde solution Substances 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000012265 solid product Substances 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000000758 substrate Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009466 transformation Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pain & Pain Management (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychiatry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO20014078A 1999-02-23 2001-08-22 Fremgangsmate for fremstilling av paroksetin NO319724B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT1999MI000364A IT1308629B1 (it)	1999-02-23	1999-02-23	Processo per la produzione di paroxetina.
PCT/EP2000/001430 WO2000050422A1 (en)	1999-02-23	2000-02-22	Process for the production of paroxetine

Publications (3)

Publication Number	Publication Date
NO20014078D0 NO20014078D0 (no)	2001-08-22
NO20014078L NO20014078L (no)	2001-10-18
NO319724B1 true NO319724B1 (no)	2005-09-05

Family

ID=11382007

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20014078A NO319724B1 (no)	1999-02-23	2001-08-22	Fremgangsmate for fremstilling av paroksetin

Country Status (28)

Country	Link
US (1)	US6583287B1 (da)
EP (1)	EP1153023B1 (da)
JP (1)	JP2002537394A (da)
KR (1)	KR20010102366A (da)
CN (1)	CN1161353C (da)
AT (1)	ATE238295T1 (da)
AU (1)	AU759441B2 (da)
BR (1)	BR0008220A (da)
CA (1)	CA2361758A1 (da)
CZ (1)	CZ20012997A3 (da)
DE (1)	DE60002303T2 (da)
DK (1)	DK1153023T3 (da)
ES (1)	ES2195876T3 (da)
HK (1)	HK1040516B (da)
HR (1)	HRP20010608A2 (da)
HU (1)	HUP0105482A3 (da)
IL (1)	IL144883A (da)
IT (1)	IT1308629B1 (da)
MX (1)	MXPA01008502A (da)
NO (1)	NO319724B1 (da)
PL (1)	PL349358A1 (da)
PT (1)	PT1153023E (da)
RU (1)	RU2242473C2 (da)
SK (1)	SK12042001A3 (da)
TR (1)	TR200102441T2 (da)
TW (1)	TWI221473B (da)
WO (1)	WO2000050422A1 (da)
YU (1)	YU60801A (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1571152B1 (en) *	2004-03-03	2007-08-08	CHEMI S.p.A.	Amorphous 3-Pyridil-1-Hydroxyethyliden-1,1-Biphosphonic acid monosodium salt and process for the preparation thereof .
US9138430B2 (en) *	2007-12-27	2015-09-22	Mylan Specialty L.P.	Formulation and method for the release of paroxetine in the large intestine
WO2013115163A1 (ja) *	2012-01-31	2013-08-08	エーザイ・アール・アンド・ディー・マネジメント株式会社	パロキセチン誘導体
CN106831736A (zh) *	2017-02-15	2017-06-13	浙江华海药业股份有限公司	一种制备帕罗西汀杂质的方法
CN112521377A (zh) *	2020-11-26	2021-03-19	北京福元医药股份有限公司	一种盐酸帕罗西汀的连续化制备方法
CN115260153B (zh) *	2022-07-21	2023-10-27	威尚（上海）生物医药有限公司	一种6取代手性纯二氟哌啶喹唑啉衍生物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0757758B2 (ja)	1988-10-24	1995-06-21	高砂香料工業株式会社	ルテニウム―ホスフィン錯体
DK715988D0 (da) *	1988-12-22	1988-12-22	Ferrosan As	Etherifikation og dealkylering af piperidin-derivater samt intermediater
US5233084A (en) *	1989-06-22	1993-08-03	Monsanto Company	Method for preparing α-arylpropionic acids
FR2651152B1 (fr) *	1989-08-23	1991-11-29	Elf Aquitaine	Perfectionnement a la preparation de catalyseurs chiraux a base de complexes du ruthenium et du phosphore.
GB9209687D0 (en) *	1992-05-06	1992-06-17	Smithkline Beecham Plc	Novel process
DE4422672A1 (de) *	1994-06-30	1996-01-04	Hoechst Ag	Halogenierte Biphenyl-2,2'-diyl-bis-diphenylphosphine, ihre Herstellung und ihre Verwendung
AR001982A1 (es) *	1995-02-06	1998-01-07	Smithkline Beecham Plc	Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
CN1068597C (zh)	1995-05-17	2001-07-18	诺沃挪第克公司	制备4－芳基－哌啶衍生物的方法
HU221921B1 (hu) *	1996-07-08	2003-02-28	Richter Gedeon Vegyészeti Gyár Rt.	N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
WO1998050359A1 (en) *	1997-05-06	1998-11-12	Novo Nordisk A/S	Novel heterocyclic compounds
ES2212287T3 (es) *	1997-05-20	2004-07-16	Firmenich Sa	Catalizadores de rutenio y su uso en la hidrogenacion asimetrica de sustratos debilmente coordinantes.

1999
- 1999-02-23 IT IT1999MI000364A patent/IT1308629B1/it active
2000
- 2000-02-18 TW TW089102997A patent/TWI221473B/zh not_active IP Right Cessation
- 2000-02-22 US US09/890,414 patent/US6583287B1/en not_active Expired - Fee Related
- 2000-02-22 ES ES00909228T patent/ES2195876T3/es not_active Expired - Lifetime
- 2000-02-22 CN CNB008041873A patent/CN1161353C/zh not_active Expired - Fee Related
- 2000-02-22 HU HU0105482A patent/HUP0105482A3/hu unknown
- 2000-02-22 JP JP2000601002A patent/JP2002537394A/ja active Pending
- 2000-02-22 PT PT00909228T patent/PT1153023E/pt unknown
- 2000-02-22 SK SK1204-2001A patent/SK12042001A3/sk unknown
- 2000-02-22 BR BR0008220-1A patent/BR0008220A/pt not_active IP Right Cessation
- 2000-02-22 YU YU60801A patent/YU60801A/sh unknown
- 2000-02-22 HR HR20010608A patent/HRP20010608A2/hr not_active Application Discontinuation
- 2000-02-22 PL PL00349358A patent/PL349358A1/xx not_active IP Right Cessation
- 2000-02-22 HK HK02101971.9A patent/HK1040516B/en not_active IP Right Cessation
- 2000-02-22 IL IL14488300A patent/IL144883A/en not_active IP Right Cessation
- 2000-02-22 AU AU31583/00A patent/AU759441B2/en not_active Ceased
- 2000-02-22 CZ CZ20012997A patent/CZ20012997A3/cs unknown
- 2000-02-22 RU RU2001125933/04A patent/RU2242473C2/ru not_active IP Right Cessation
- 2000-02-22 DE DE60002303T patent/DE60002303T2/de not_active Expired - Fee Related
- 2000-02-22 WO PCT/EP2000/001430 patent/WO2000050422A1/en not_active Ceased
- 2000-02-22 EP EP00909228A patent/EP1153023B1/en not_active Expired - Lifetime
- 2000-02-22 AT AT00909228T patent/ATE238295T1/de not_active IP Right Cessation
- 2000-02-22 DK DK00909228T patent/DK1153023T3/da active
- 2000-02-22 CA CA002361758A patent/CA2361758A1/en not_active Abandoned
- 2000-02-22 MX MXPA01008502A patent/MXPA01008502A/es active IP Right Grant
- 2000-02-22 KR KR1020017010760A patent/KR20010102366A/ko not_active Ceased
- 2000-02-22 TR TR2001/02441T patent/TR200102441T2/xx unknown
2001
- 2001-08-22 NO NO20014078A patent/NO319724B1/no unknown

Also Published As

Publication number	Publication date
ATE238295T1 (de)	2003-05-15
CZ20012997A3 (cs)	2001-11-14
DK1153023T3 (da)	2003-08-11
HK1040516B (en)	2003-10-31
DE60002303T2 (de)	2004-04-01
HUP0105482A3 (en)	2002-11-28
SK12042001A3 (sk)	2001-12-03
MXPA01008502A (es)	2003-06-06
HK1040516A1 (en)	2002-06-14
EP1153023B1 (en)	2003-04-23
ITMI990364A1 (it)	2000-08-23
WO2000050422A1 (en)	2000-08-31
YU60801A (sh)	2005-07-19
NO20014078D0 (no)	2001-08-22
CN1341113A (zh)	2002-03-20
HRP20010608A2 (en)	2002-08-31
KR20010102366A (ko)	2001-11-15
BR0008220A (pt)	2001-11-06
AU3158300A (en)	2000-09-14
CA2361758A1 (en)	2000-08-31
HUP0105482A2 (en)	2002-08-28
TWI221473B (en)	2004-10-01
ES2195876T3 (es)	2003-12-16
IL144883A (en)	2004-12-15
DE60002303D1 (de)	2003-05-28
US6583287B1 (en)	2003-06-24
TR200102441T2 (tr)	2002-01-21
JP2002537394A (ja)	2002-11-05
RU2242473C2 (ru)	2004-12-20
PL349358A1 (en)	2002-07-15
IT1308629B1 (it)	2002-01-09
IL144883A0 (en)	2002-06-30
AU759441B2 (en)	2003-04-17
PT1153023E (pt)	2003-09-30
CN1161353C (zh)	2004-08-11
EP1153023A1 (en)	2001-11-14
NO20014078L (no)	2001-10-18

Publication	Publication Date	Title
RU2753548C1 (ru)	2021-08-17	Способ производства никотина
RS60801B1 (sr)	2020-10-30	Tečni farmaceutski sastav
KR102037494B1 (ko)	2019-10-28	광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
EP2589587A1 (en)	2013-05-08	Synthesis of nitrogen substituted cyclopropanes
ES2214047T3 (es)	2004-09-01	Procedimiento para la disociacion de racematos de acidos 2-hidroxipropionicos.
JP6137185B2 (ja)	2017-05-31	（ｒ）−１，１，３−トリメチル−４−アミノインダンの製造方法
NO319724B1 (no)	2005-09-05	Fremgangsmate for fremstilling av paroksetin
SK3332003A3 (en)	2003-07-01	Chromanone derivative, process for its preparation and its use
ZA200105840B (en)	2002-10-16	Chroman derivatives.
JP2011236157A (ja)	2011-11-24	光学活性ニペコチン酸誘導体の製造方法
CN113072486B (zh)	2024-10-11	氨基醇-硼-联萘酚配合物及利用该配合物的光学活性氨基醇衍生物的制备方法
JP2002537394A5 (da)	2007-04-12
JP5031778B2 (ja)	2012-09-26	光学活性な２−（アロイルオキシ）プロピオン酸を用いたアミン化合物の製造方法
JP2014012713A (ja)	2014-01-23	２，６−ｔｒａｎｓ−ジメチルモルホリンのラセミ分離
DE60006125T2 (de)	2004-07-08	Herstellung von 2-(2-arylmorpholin-2-yl)ethanolderivaten und zwischenprodukte
Voight et al.	2010	Efficient and general asymmetric syntheses of (R)-chroman-4-amine salts
JPS63503384A (ja)	1988-12-08	１‐置換（ｓ）‐および（ｒ）‐２‐アミノメチルピロリジン類の有効な立体保存的合成およびその中間体
JP5616977B2 (ja)	2014-10-29	光学活性アルコール化合物の製造方法
Kotian et al.	2005	An efficient stereoselective synthesis of (3S, 4R)-4-(hydroxymethyl) pyrrolidin-3-ol from (S)-diethylmalate
JP2002371060A (ja)	2002-12-26	光学活性アミノピペリジン誘導体の製造方法
CN119306645A (zh)	2025-01-14	制备吡咯酰胺化合物的方法及其中间体
CN117604061A (zh)	2024-02-27	(+)-α-羟基丁苯那嗪的中间体化合物及其制备方法
KR20080076009A (ko)	2008-08-20	Ｓ-(-)-암로디핀 또는 이의 염의 제조방법 및 이에사용되는 중간체
KR20190120112A (ko)	2019-10-23	광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
KR20170037240A (ko)	2017-04-04	광학활성을 가진 티에닐알라닌의 제조 방법